Last reviewed · How we verify

NCT06143865

Closed Aspiration on Hemodynamic Changes and Pain

Completed NA Last updated 12 December 2025
What this trial tests

NA trial testing Closed system aspiration in Aspiration in 67 participants. Completed in 10 October 2023.

Timeline
10 July 2022
Primary endpoint
10 November 2022
10 October 2023

Quick facts

Lead sponsorIzmir Bakircay University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment67
Start date10 July 2022
Primary completion10 November 2022
Estimated completion10 October 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Izmir Bakircay University

Who can join

Adults 18 to 65, any sex, with Aspiration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was planned to determine the effects of closed aspiration on arterial blood pressure, heart rate, respiratory rate, oxygen saturation level and pain in intensive care patients connected to mechanical ventilators. IThe effects of the closed aspiration system on hemodynamic parameters and pain will be determined and the results will be important in terms of the usability of the closed system in the clinical environment and raising awareness in nursing practices in order to create minimum complications for the patient.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aspiration

Currently open trials in the same condition.

Other Izmir Bakircay University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06143865.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing